Octreotide therapy in eye disease caused due to thyroid disorders
Not Applicable
- Conditions
- Health Condition 1: H578- Other specified disorders of eye and adnexa
- Registration Number
- CTRI/2019/11/022116
- Lead Sponsor
- Research Section AIIMS New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a) patients with Graves orbitopathy with failed first line of intravenous steroid therapy, before starting second line b) age more than 18 years c) Clinical activity score more than 3 d) with contraindication for other immunosuppressive therapy
Exclusion Criteria
1) Pregnant and lactating women. 2) Patient on another immunosuppressive therapy 3) patients urgently needing surgical decompression 4) Impending Dysthroid optic neuropathy (DON) 5) Patients in whom urgent second line therapy is required
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)To assess somatostatin receptor expression in orbital soft tissue with Ga 68 DOTANOC PET/CT <br/ ><br>2) To evaluate response to both steroid and steroid plus octreotide therapy in the two groups of patients with somatostatin receptor expressing Graves orbitopathy by CAS, EUGOGO scoring, Exophthalmometry, field charting, acuity testing, colour vision testing and achievement of cosmesis at 3 and 6 month intervals after therapy <br/ ><br> <br/ ><br> <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: Patient Recruitment 0-24 months <br/ ><br>SSTR PET/CT 0-24 MONTHS <br/ ><br>Octreotide Therapy 0-24months <br/ ><br>Follow up 0-30 months <br/ ><br>Data Analysis 30-36 months
- Secondary Outcome Measures
Name Time Method not applicableTimepoint: not applicable